The US company Moderina first began testing the vaccine on humans in March to prevent the new novel Corona virus, which is now in its second phase.
But now preliminary results from experiments on the vaccine in mice have been released, which show that it does not cause serious severity of code 19 and that a single dose of it could potentially protect against the novice corona virus. Û”
Research reports on vaccine development to control the epidemic of the SARS corona virus, which is considered to be genetically very close to the new corona virus, indicated in 2002 and 2003 that the prevention of such a virus Vaccines developed for can inadvertently increase the severity of the disease when the person who was vaccinated against the virus is exposed again.
Especially people who have not developed a strong immune response to the virus.
Scientists were calling the threat a major obstacle to the development of a vaccine against the novel coronavirus.
Now the US National Institute of Allergy and Infectious Diseases and Moderina have released the results of a test on mice that has been described as encouraging, but does not guarantee that it will occur in humans.
In a new study on mice, 6-week-old mice were given one or two doses of the Moderina vaccine in different doses, while some were given the dose in such a small amount that it was thought to be effective in counteracting the ill effects of the immune system. not enough.
The rats were then infected with the virus.
Subsequent analysis of the symptoms of the disease revealed that the immune system’s immune system did not have the effects that would normally be seen in a vaccine for a respiratory disease, a more serious lung disease.
The researchers said that even small doses did not show the effects of the virus in mice.
Further testing also indicated that the vaccine produced an antibody response that is needed to block the virus that infects cells.
The researchers also found that the vaccine also protects against infections caused by the corona virus in the lungs and nose, while no toxic effects have been reported.
He said that the mice, which were given only one dose of the vaccine seven weeks before they were infected with the virus, also received complete protection against the virus in their lungs, suggesting that the virus could transmit to the lungs once vaccinated. Can be prevented from creating.
Other experts say that at first glance, the results of the vaccine on mice are encouraging because it also provides antibody protection.
The first round of trials of the vaccine on humans was launched in May, and the company said it had developed an immune response seen in patients who had recovered from code 19.
“The results of this provisional Phase 1 data are preliminary, but it shows that people who have been vaccinated have developed an immune response that helps fight the virus,” said Ty Zax, the company’s chief medical officer.
“This data further strengthens our belief that MRNA 1273 has the ability to block code 19 and that this capability will be further enhanced in new trials,” he added.
The company claims that the vaccine is safe and that patients do not experience redness or swelling of the skin when used.
The US government is spending about کروڑ 500 million on the vaccine, which is being developed by the company in partnership with the National Institute of Allergy and Infectious Diseases, headed by Dr. Anthony Fauchi.
In the first phase of the trial, people aged 18 to 55 were given three different doses of the vaccine, the full results of which have not yet been released.
Work is currently underway on the second phase.
In the second phase, researchers are testing its efficacy and side effects in 600 people.
The third phase of the trial will be the largest and most important in which work will be done to prove the effectiveness of the vaccine and it will start in July.
According to the company’s CEO, the research team’s focus is on launching the third phase as early as July.
Following the partial results of the first phase, the company also stated that it was not researching higher doses because lower doses were having a positive effect.
Millions of people will be hired for the third phase to determine if the vaccine is effective and does not cause any harm.
After the third phase, the FDA will decide to approve the use of this vaccine and this approval will be given only if it proves to be safe and effective while its benefits outweigh the risks.
The statement said more people would be protected from the virus than those from the lower echelons.
It is believed that it usually takes many years to develop a vaccine, but due to the rapid spread of the coronavirus, the vaccine is being developed very fast.
Human trials of the vaccine are also underway in China, Britain and Germany, and China says it will test five vaccines on humans.
In fact, China plans to be the first in the world to develop a vaccine against the corona virus.
But it is not only a challenge to make the vaccine effective and safe, but also to provide billions of doses.
Numerous companies, including Modern
It has announced that it will begin mass production of the vaccine before all clinical trials are completed.
Moderina has announced a partnership with Lonza, a major pharmaceutical company, for this purpose, with the potential to produce one billion doses a year.
It should be noted that this vaccine uses a new technology that has not been used in any other approved vaccine so far.
Most conventional vaccines use a weakened or weakened version of the virus to train the body’s immune system to fight it, but this new vaccine uses a molecular messenger RNA that allows cells to make viral proteins on their own. Directs
MRNA directs cells to make spike proteins from the corona virus, which the virus uses to infect human cells.
The idea is that it will help the immune system identify spike proteins and make antibodies against them.
The technology is being described as a faster method of vaccine development and more stable than conventional vaccines.